Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WIRE: Window of Opportunity Trial in Renal Cell Cancer
NCT03741426Phase 2Recruiting
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Jul 2020
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaparib, cediranib, volrustomig and rilvegostomig in renal cell carcinoma (RCC) (5 arms), sponsored by Cambridge Clinical Trials Unit. Primary endpoints: Proof-of-Mechanism (ktrans) and Proof-of-Mechanism (CD8). Started Jul 2020; status: recruiting.
02
Drugs
olaparibcediranibvolrustomigrilvegostomig
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03741426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03741426.